Since little MAPK inhibitor information on these side effects is available in Iran, this study was designed to obtain more information. Patients were interviewed by a psychoneurologist about any sexual dysfunction and the information was recorded. Materials and methods This was an observational cross-sectional study. Patients presenting to the neuropsychology clinic at the university hospital or specialist clinics in the city of Lorestan from March 2011 to March 2012 who were diagnosed Inhibitors,research,lifescience,medical with depression

after clinical evaluation based on Diagnostic and Statistical Manual of Mental Disorders fourth edition text revision (DSM-IV-TR) criteria, who gave informed consent to participate and were taking antidepressant medication were included. Patients with a Inhibitors,research,lifescience,medical previous history of psychotropic medication use, psychiatric conditions or sexual dysfunction were excluded.

All patients were re-evaluated after 2, 4 and 8 weeks of treatment initiation. At each visit, the evaluation was carried out by a neuropsychologist and all four parts of sexual functioning were assessed and any change recorded. Data were entered into the computer and analysed using SPSS software and presented in the form of distribution tables. Correlations were assessed using t and χ2 tests. Results Patients Inhibitors,research,lifescience,medical included in the study were between 18 and 50 years of age. Most were in the age range of 28–37 years (44 patients, 44%). The mean age of patients was 31.11 ± 7.48 Inhibitors,research,lifescience,medical years and the mean age of patients

with sexual dysfunction was 31.33 ± 7.80 years. A total of 23% of patients in the age range 18–27 years and 33% of patients in the age range 28–37 years had sexual dysfunction. In addition, 19% of patients in the age range 38–50 years developed sexual dysfunction. Sexual dysfunction was most prevalent in the age range 28–37 (33%) (Figure 1). Figure 1. Distribution Inhibitors,research,lifescience,medical of sexual dysfunction based on age. A total of 36% of patients were men, of which 24 (66.7%) reported sexual dysfunction. Of the remaining 64% female patients were women, 51 (79.7%) developed dysfunction. There PDK4 was no significant difference noted in the incidence of sexual dysfunction between men and women (p = 0.16) (Table 1). Table 1. Distribution of sexual dysfunction based on sex. A total of 91% were married and 9% were single. Highest completed education levels were as follows: 8% had completed primary school education; 23% had completed junior high school education; 51% had a high-school diploma; and 18% were university graduates, as shown in Figure 2. Figure 2. Distribution of sexual dysfunction based on education and sex. The SSRI medication used was fluvoxamine in 58%, fluoxetine in 4%, sertraline in 16%, citalopram in 21% and paroxetine in 1% (Figure 3). Figure 3. Distribution of sexual dysfunction based on kind of antidepressant.